Vicente Herrero-Aguayo

List of Publications by Year
in descending order

12	200	1040056 9	1199594 12
papers	citations	h-index	g-index

12	12	12	249
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. Translational Research, 2019, 212, 89-103.	5.0	47
2	Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. Journal of Experimental and Clinical Cancer Research, 2021, 40, 382.	8.6	25
3	Influence of Obesity in the miRNome: miR-4454, a Key Regulator of Insulin Response Via Splicing Modulation in Prostate. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e469-e484.	3.6	20
4	Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e696-e710.	3.6	19
5	Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and <scp>IGF</scp>1. Journal of Cellular and Molecular Medicine, 2017, 21, 1893-1904.	3.6	17
6	Plasma ghrelin Oâ€acyltransferase (GOAT) enzyme levels: A novel nonâ€invasive diagnosis tool for patients with significant prostate cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 5688-5697.	3.6	17
7	Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. Journal of Clinical Medicine, 2019, 8, 1400.	2.4	16
8	Mouse models of endocrine tumors. Journal of Endocrinology, 2019, 240, R73-R96.	2.6	12
9	Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells. Antioxidants, 2021, 10, 1348.	5.1	10
10	Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. Journal of Clinical Medicine, 2019, 8, 2056.	2.4	8
11	Unleashing the Diagnostic, Prognostic and Therapeutic Potential of the Neuronostatin/GPR107 System in Prostate Cancer. Journal of Clinical Medicine, 2020, 9, 1703.	2.4	5
12	Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool. Molecular Therapy - Nucleic Acids, 2022, 27, 1164-1178.	5.1	4